1
|
Lin SW, Chen CY, Chen PC, Feng CL, Lin HY, Chen JH. Assessing risk of recurrent small bowel obstruction after non-operative management in patients with history of intra-abdominal surgery: a population-based comprehensive analysis in Taiwan. Surg Endosc 2024; 38:2433-2443. [PMID: 38453749 DOI: 10.1007/s00464-024-10746-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2023] [Accepted: 02/06/2024] [Indexed: 03/09/2024]
Abstract
BACKGROUND Despite a significant 30% ten-year readmission rate for SBO patients, investigations into recurrent risk factors after non-operative management are scarce. The study aims to generate a risk factor scoring system, the 'Small Bowel Obstruction Recurrence Score' (SBORS), predicting 6-month recurrence of small bowel obstruction (SBO) after successful non-surgical management in patients who have history of intra-abdominal surgery. METHODS We analyzed data from patients aged ≥ 18 with a history of intra-abdominal surgery and diagnosed with SBO (ICD-9 code: 560, 568) and were successful treated non-surgically between 2004 and 2008. Participants were divided into model-derivation (80%) and validation (20%) group. RESULTS We analyzed 23,901 patients and developed the SBORS based on factors including the length of hospital stay > 4 days, previous operations > once, hemiplegia, extra-abdominal and intra-abdominal malignancy, esophagogastric surgery and intestino-colonic surgery. Scores > 2 indicated higher rates and risks of recurrence within 6 months (12.96% vs. 7.27%, OR 1.898, p < 0.001 in model-derivation group, 12.60% vs. 7.05%, OR 1.901, p < 0.001 in validation group) with a significantly increased risk of mortality and operative events for recurrent episodes. The SBORS model demonstrated good calibration and acceptable discrimination, with an area under curve values of 0.607 and 0.599 for the score generation and validation group, respectively. CONCLUSIONS We established the effective 'SBORS' to predict 6-month SBO recurrence risk in patients who have history of intra-abdominal surgery and have been successfully managed non-surgically for the initial obstruction event. Those with scores > 2 face higher recurrence rates and operative risks after successful non-surgical management.
Collapse
Affiliation(s)
- Shang-Wei Lin
- Division of Plastic Surgery, Department of Surgery, Cathay General Hospital, Taipei, 10630, Taiwan
- Department of Surgery, Cathay General Hospital, Taipei, 10630, Taiwan
| | - Chung-Yen Chen
- Division of General Surgery, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan
- Bariatric and Metabolism International Surgery Center, E-Da Hospital, Kaohsiung, Taiwan
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan
| | - Pin-Chun Chen
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan
- Division of Colon & Rectal Surgery, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan
| | - Che-Lun Feng
- Division of General Surgery, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan
| | - Hung-Yu Lin
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
- Division of Urology, Department of Surgery, E-Da Cancer & E-Da Hospital, Kaohsiung, Taiwan.
| | - Jian-Han Chen
- Division of General Surgery, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan.
- Bariatric and Metabolism International Surgery Center, E-Da Hospital, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
| |
Collapse
|
2
|
Lin SW, Chen CY, Su YC, Wu KT, Yu PC, Yen YC, Chen JH. Mortality Prediction Model before Surgery for Acute Mesenteric Infarction: A Population-Based Study. J Clin Med 2022; 11:jcm11195937. [PMID: 36233806 PMCID: PMC9571294 DOI: 10.3390/jcm11195937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2022] [Revised: 09/28/2022] [Accepted: 10/05/2022] [Indexed: 12/02/2022] Open
Abstract
Surgery for acute mesenteric infarction (AMI) is associated with high mortality. This study aimed to generate a mortality prediction model to predict the 30-day mortality of surgery for AMI. We included patients ≥18 years who received bowel resection in treating AMI and randomly divided into the derivation and validation groups. After multivariable analysis, the ‘Surgery for acute mesenteric infarction mortality score’ (SAMIMS) system was generated and was including age >62-year-old (3 points), hemodialysis (2 points), congestive heart failure (1 point), peptic ulcer disease (1 point), diabetes (1 point), cerebrovascular disease (1 point), and severe liver disease (4 points). The 30-day-mortality rates in the derivation group were 4.4%, 13.4%, 24.5%, and 32.5% among very low (0 point), low (1−3 point(s)), intermediate (4−6 points), and high (7−13 points)-risk patients. Compared to the very-low-risk group, the low-risk (OR = 3.332), intermediate-risk (OR = 7.004), and high-risk groups (OR = 10.410, p < 0.001) exhibited higher odds of 30-day mortality. We identified similar results in the validation group. The areas under the ROC curve were 0.677 and 0.696 in the derivation and validation groups. Our prediction model, SAMIMS, allowed for the stratification of the patients’ 30-day-mortality risk of surgery for acute mesenteric infarction.
Collapse
Affiliation(s)
- Shang-Wei Lin
- Department of Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
- Healthcare Group Department of Medical Education, E-Da Hospital, Kaohsiung 82445, Taiwan
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
| | - Chung-Yen Chen
- Department of Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
- Division of General Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
- Bariatric and Metabolism International Surgery Center, E-Da Hospital, Kaohsiung 82445, Taiwan
| | - Yu-Chieh Su
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
- Division of Hematology-Oncology, E-Da Hospital, Kaohsiung 82445, Taiwan
| | - Kun-Ta Wu
- Department of Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
- Division of General Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
| | - Po-Chin Yu
- Department of Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
- Division of General Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
| | - Yung-Chieh Yen
- Department of Psychiatry, E-Da Hospital, Kaohsiung 82445, Taiwan
- Correspondence: (Y.-C.Y.); (J.-H.C.)
| | - Jian-Han Chen
- Department of Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
- School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan
- Division of General Surgery, E-Da Hospital, Kaohsiung 82445, Taiwan
- Bariatric and Metabolism International Surgery Center, E-Da Hospital, Kaohsiung 82445, Taiwan
- Correspondence: (Y.-C.Y.); (J.-H.C.)
| |
Collapse
|
3
|
Abstract
Background The likelihoods of valvular heart disease ( VHD ) and conduction abnormalities in patients with ankylosing spondylitis ( AS p) are poorly defined. Knowing their lifetime risks of VHD and pacemaker use would help inform whether cardiac screening should be done. Methods and Results Patients with AS p and a comparison group without AS p were identified among US Medicare beneficiaries in 1999 to 2013. Frequencies of VHD and pacemaker use were compared in 4 age groups: 65 to 69 years, 70 to 74 years, 75 to 79 years, and 80 years or older, as were rates of valve surgeries, a measure of VHD severity, and new pacemaker insertions. Outcomes were compared between 42 327 patients with AS p and 19 211 703 patients without AS p. The prevalence of aortic valve disease in patients with AS p increased with age (2.6%, 6.7%, 10.9%, and 17.1%), as did the prevalence of mitral valve disease. Risks of VHD were slightly but significantly higher in patients with AS p (adjusted odds ratios 1.06-1.51). Rates of aortic valve replacement/repair were also higher in patients with AS p than in the comparison group (125 versus 93; 183 versus 149; 261 versus 208; 279 versus 191 per 100 000 patient-years in the 4 age groups). Rates of mitral valve surgery did not differ between groups. Among patients with AS p, pacemaker use ranged from 1.0% to 7.6% across age groups, and was slightly higher than in controls (odds ratio range 1.11-1.32). Conclusions Lifetime risks of VHD and pacemaker use in AS p increase markedly with age, but are only slightly higher than in elderly people without AS p.
Collapse
Affiliation(s)
- Michael M Ward
- 1 Intramural Research Program National Institute of Arthritis and Musculoskeletal and Skin Diseases National Institutes of Health Bethesda MD
| |
Collapse
|
4
|
Basil G, Madhavan K, Komotar RJ, Carrillo R, Levi AD. The Utility of Magnetic Resonance Imaging-compatible Pacemakers in Neurosurgical Patients. Cureus 2018; 10:e3374. [PMID: 30510883 PMCID: PMC6257712 DOI: 10.7759/cureus.3374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022] Open
Abstract
Artificial implantable pacemakers have long been a challenge to neurosurgeons seeking to perform advanced diagnostic imaging on their patients. Unfortunately, while the use of implantable pacemakers has been a life-saving advance for those with cardiac arrhythmias, they also often prevent these patients from undergoing magnetic resonance imaging (MRI). There have been multiple reported cases of pacemaker failure in the context of MRI use. Recent technological advances, however, have allowed the development of pacemakers that are not affected by the MRI scanner. Similar technology has also been applied to the development of MRI-compatible spinal cord stimulators and other neurostimulation devices. In this paper, we discuss four specific neurosurgical cases where the use of MRI was critical for diagnostic and therapeutic decision-making. Current non-MRI-compatible pacemakers were exchanged for MRI-compatible pacemaker technology with some associated cost and risk. The diagnostic cranial and spinal MRIs subsequently obtained were critical for forging the ensuing neurosurgical care. Based on these cases, we extrapolate the importance of MRI-compatible pacemakers to society at large and advocate for the use of such devices in all patients going forward.
Collapse
Affiliation(s)
- Gregory Basil
- Neurological Surgery, University of Miami Miller School of Medicine, Miami, USA
| | - Karthik Madhavan
- Neurological Surgery, University of Miami Miller School of Medicine, Miami, USA
| | - Ricardo J Komotar
- Neurological Surgery, University of Miami Miller School of Medicine, Miami, USA
| | - Roger Carrillo
- Cardiothoracic Surgery, University of Miami Miller School of Medicine, Miami, USA
| | - Allan D Levi
- Neurological Surgery, University of Miami Miller School of Medicine, Miami, USA
| |
Collapse
|
5
|
Roberts PR, Zachariah D, Morgan JM, Yue AM, Greenwood EF, Phillips PC, Kalra PA, Green D, Lewis RJ, Kalra PR. Monitoring of arrhythmia and sudden death in a hemodialysis population: The CRASH-ILR Study. PLoS One 2017; 12:e0188713. [PMID: 29240772 PMCID: PMC5730159 DOI: 10.1371/journal.pone.0188713] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Accepted: 10/22/2017] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION It has been suggested that sudden cardiac death (SCD) contributes around 50% of cardiovascular and 27% of all-cause mortality in hemodialysis patients. The true burden of arrhythmias and arrhythmic deaths in this population, however, remains poorly characterised. Cardio Renal Arrhythmia Study in Hemodialysis (CRASH-ILR) is a prospective, implantable loop recorder single centre study of 30 established hemodialysis patients and one of the first to provide long-term ambulatory ECG monitoring. METHODS 30 patients (60% male) aged 68±12 years receiving hemodialysis for 45±40 months with varied etiology (diabetes 37%, hypertension 23%) and left ventricular ejection fraction (LVEF) 55±8% received a Reveal XT implantable loop recorder (Medtronic, USA) between August 2011 and October 2014. ECG data from loop recorders were transmitted at each hemodialysis session using a remote monitoring system. Primary outcome was SCD or implantation of a (tachy or bradyarrhythmia controlling) device and secondary outcome, the development of arrhythmia necessitating medical intervention. RESULTS During 379,512 hours of continuous ECG monitoring (mean 12,648±9,024 hours/patient), there were 8 deaths-2 SCD and 6 due to generalised deterioration/sepsis. 5 (20%) patients had a primary outcome event (2 SCD, 3 pacemaker implantations for bradyarrhythmia). 10 (33%) patients reached an arrhythmic primary or secondary end point. Median event free survival for any arrhythmia was 2.6 years (95% confidence intervals 1.6-3.6 years). CONCLUSIONS The findings confirm the high mortality rate seen in hemodialysis populations and contrary to initial expectations, bradyarrhythmias emerged as a common and potentially significant arrhythmic event.
Collapse
Affiliation(s)
- Paul R. Roberts
- Southampton University Hospitals, Southampton, United Kingdom
| | | | - John M. Morgan
- Southampton University Hospitals, Southampton, United Kingdom
| | - Arthur M. Yue
- Southampton University Hospitals, Southampton, United Kingdom
| | | | | | | | | | | | - Paul R. Kalra
- Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom
| |
Collapse
|
6
|
Implantable cardioverter defibrillators and permanent pacemakers: prevalence and patient outcomes after trauma. Am J Surg 2016; 212:953-960. [DOI: 10.1016/j.amjsurg.2016.07.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2016] [Revised: 07/08/2016] [Accepted: 07/13/2016] [Indexed: 11/18/2022]
|
7
|
Bradshaw PJ, Stobie P, Einarsdóttir K, Briffa TG, Hobbs MST. Using quality indicators to compare outcomes of permanent cardiac pacemaker implantation among publicly and privately funded patients. Intern Med J 2015; 45:813-20. [PMID: 25851227 DOI: 10.1111/imj.12762] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2014] [Accepted: 03/30/2015] [Indexed: 11/29/2022]
Abstract
BACKGROUND Funding source/insurance status has been associated with disparity in the management and outcomes of cardiovascular disease, with poorer outcomes among disadvantaged groups. AIM Using proposed quality indicators for permanent pacemaker (PPM) implantation and administrative data, this study aimed to determine whether quality indicator-based outcomes of PPM implantation were comparable for publicly and privately funded patients within Australia's two-tier health system. METHODS A population-based cohort study of adults implanted with a PPM between 1995 and 2009 in Western Australia. The association of funding outcomes derived from linked administrative data was tested in multivariate logistic regression models. RESULTS There were 9748 PPMs implanted, 48% being among privately funded patients. The mean age was 75 years for both public and private patients. Private patients had better health status (fewer with cardiac conditions and lower non-cardiac comorbidity scores), were less likely to be an emergency admission (33% vs 60%, P < 0.001) and more likely to have dual- or triple-chamber pacing. Mean length of stay was significantly greater for private patients (4.3 (standard deviation 6.3) vs 5.1 (6.8) days <0.001), related to longer elective admissions. Crude mortality was lower for private patients in-hospital (0.7 vs 1.3%), 30-day post-procedure (1.3 vs 2.1%) and at 1 year (7.3 vs 9.5%). Emergency admission, comorbidity and other demographic and clinical factors, not funding source, were significant predictors of these outcomes. CONCLUSIONS There was no difference between publicly and privately funded patients in study outcomes, after adjustment for demographic and clinical factors. The exception was longer hospital stay for elective PPM among privately funded patients.
Collapse
Affiliation(s)
- P J Bradshaw
- Cardiovascular Research Group, The University of Western Australia, Perth, Western Australia, Australia
| | - P Stobie
- School of Medicine and Pharmacology, Sir Charles Gairdner Hospital and The University of Western Australia, Perth, Western Australia, Australia
| | - K Einarsdóttir
- Centre for Health Services Research, School of Population Health, The University of Western Australia, Perth, Western Australia, Australia.,Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia
| | - T G Briffa
- Cardiovascular Research Group, The University of Western Australia, Perth, Western Australia, Australia
| | - M S T Hobbs
- Cardiovascular Research Group, The University of Western Australia, Perth, Western Australia, Australia
| |
Collapse
|
8
|
Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MST. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart 2014; 1:e000177. [PMID: 25512875 PMCID: PMC4265147 DOI: 10.1136/openhrt-2014-000177] [Citation(s) in RCA: 120] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Revised: 11/11/2014] [Accepted: 11/18/2014] [Indexed: 11/03/2022] Open
Abstract
OBJECTIVES To determine contemporary population estimates of the prevalence of cardiac permanent pacemaker (PPM) insertions. METHODS A population-based observational study using linked hospital morbidity and death registry data from Western Australia (WA) to identify all incident cases of PPM insertion for adults aged 18 years or older. Prevalence rates were calculated by age and sex for the years 1995-2009 for the WA population. RESULTS There were 9782 PPMs inserted during 1995-2009. Prevalence rose across the study period, exceeding 1 in 50 among people aged 75 or older from 2005. This was underpinned by incidence rates which rose with age, being highest in those 85 years or older; over 500/100 000 for men throughout, and over 200/100 000 for women. Rates for patients over 75 were more than double the rates for those aged 65-74 years. Women were around 40% of cases overall. The use of dual-chamber and triple-chamber pacing increased across the study period. A cardiac resynchronisation defibrillator was implanted for 58% of patients treated with cardiac resynchronisation therapy. CONCLUSIONS Rates of insertion and prevalence of PPM continue to rise with the ageing population in WA. As equilibrium has probably not been reached, the demand for pacing services in similarly well-developed economies is likely to continue to grow.
Collapse
Affiliation(s)
- Pamela J Bradshaw
- School of Population Health, The University of Western Australia , Perth, Western Australia , Australia
| | - Paul Stobie
- Department of Cardiovascular Medicine , Sir Charles Gairdner Hospital, Perth, Western Australia , Australia
| | - Matthew W Knuiman
- School of Population Health, The University of Western Australia , Perth, Western Australia , Australia
| | - Thomas G Briffa
- School of Population Health, The University of Western Australia , Perth, Western Australia , Australia
| | - Michael S T Hobbs
- School of Population Health, The University of Western Australia , Perth, Western Australia , Australia
| |
Collapse
|
9
|
Brooks JM, Tang Y, Chapman CG, Cook EA, Chrischilles EA. What is the effect of area size when using local area practice style as an instrument? J Clin Epidemiol 2013; 66:S69-83. [PMID: 23849157 DOI: 10.1016/j.jclinepi.2013.04.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2012] [Revised: 03/06/2013] [Accepted: 04/08/2013] [Indexed: 10/26/2022]
Abstract
OBJECTIVES Discuss the tradeoffs inherent in choosing a local area size when using a measure of local area practice style as an instrument in instrumental variable estimation when assessing treatment effectiveness. STUDY DESIGN Assess the effectiveness of angiotensin converting-enzyme inhibitors and angiotensin receptor blockers on survival after acute myocardial infarction for Medicare beneficiaries using practice style instruments based on different-sized local areas around patients. We contrasted treatment effect estimates using different local area sizes in terms of the strength of the relationship between local area practice styles and individual patient treatment choices; and indirect assessments of the assumption violations. RESULTS Using smaller local areas to measure practice styles exploits more treatment variation and results in smaller standard errors. However, if treatment effects are heterogeneous, the use of smaller local areas may increase the risk that local practice style measures are dominated by differences in average treatment effectiveness across areas and bias results toward greater effectiveness. CONCLUSION Local area practice style measures can be useful instruments in instrumental variable analysis, but the use of smaller local area sizes to generate greater treatment variation may result in treatment effect estimates that are biased toward higher effectiveness. Assessment of whether ecological bias can be mitigated by changing local area size requires the use of outside data sources.
Collapse
Affiliation(s)
- John M Brooks
- University of Iowa, College of Pharmacy and College of Public Health, S-515 Pharmacy Bldg., 115 S. Grand Ave, Iowa City, IA 52242, USA.
| | | | | | | | | |
Collapse
|
10
|
Follow-up of patients with new cardiovascular implantable electronic devices: is adherence to the experts' recommendations associated with improved outcomes? Heart Rhythm 2013; 10:1127-33. [PMID: 23773989 DOI: 10.1016/j.hrthm.2013.06.009] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2013] [Indexed: 11/23/2022]
Abstract
BACKGROUND A 2008 expert consensus statement recommended an in-person follow-up visit between 2 and 12 weeks after the placement of a new cardiovascular implantable electronic device (CIED). OBJECTIVE To assess outcomes associated with adherence to the experts' recommendations. METHODS By using data from the National Cardiovascular Data Registry's (NCDR) ICD Registry linked to Medicare claims, we studied the association between follow-up within 2-12 weeks after CIED placement between January 1, 2005, and September 30, 2008, and all-cause mortality and risk of readmission within 1 year. RESULTS Compared with patients who did not receive the recommended follow-up (n = 43,060), those who did (n = 30,256) were more likely to be older, white, to have received a cardiac resynchronization therapy-defibrillator device, to have more advanced heart failure symptoms, and to have nonischemic dilated cardiomyopathy. In Cox proportional hazards models adjusted for patient demographic and clinical factors, mortality was lower (hazard ratio [HR] 0.93; 95% confidence interval [CI] 0.88-0.98; P = .005) but cardiovascular readmission was higher (HR 1.04; 95% CI 1.01-1.08; P = .012) among patients who received initial follow-up within 2-12 weeks after CIED placement compared with those who did not. There was no association between CIED follow-up and readmission for heart failure (HR 1.00; 95% CI 0.96-1.05; P = .878) or device-related infection (HR 1.22; 95% CI 0.98-1.51; P = .075). CONCLUSIONS Follow-up within 2-12 weeks after CIED placement was independently associated with improved survival but increased cardiovascular readmission. Quality improvement initiatives designed to increase adherence to experts' recommendations may be warranted.
Collapse
|
11
|
Al-Khatib SM, Mi X, Wilkoff BL, Qualls LG, Frazier-Mills C, Setoguchi S, Hess PL, Curtis LH. Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice? Circ Arrhythm Electrophysiol 2012; 6:108-16. [PMID: 23264436 DOI: 10.1161/circep.112.974337] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND A 2008 expert consensus statement outlined the minimum frequency of follow-up of patients with cardiovascular implantable electronic devices (CIEDs). METHODS AND RESULTS We studied 38 055 Medicare beneficiaries who received a new CIED between January 1, 2005, and June 30, 2009. The main outcome measure was variation of follow-up by patient factors and year of device implantation. We determined the number of patients who were eligible for and attended an in-person CIED follow-up visit within 2 to 12 weeks, 0 to 16 weeks, and 1 year after implantation. Among eligible patients, 42.4% had an initial in-person visit within 2 to 12 weeks. This visit was significantly more common among white patients than black patients and patients of other races (43.0% versus 36.8% versus 40.5%; P<0.001). Follow-up within 2 to 12 weeks improved from 40.3% in 2005 to 55.1% in 2009 (P<0.001 for trend). The rate of follow-up within 0 to 16 weeks was 65.1% and improved considerably from 2005 to 2009 (62.3%-79.6%; P<0.001 for trend). Within 1 year, 78.0% of the overall population had at least 1 in-person CIED follow-up visit. CONCLUSIONS Although most Medicare beneficiaries who received a new CIED between 2005 and 2009 did not have an initial in-person CIED follow-up visit within 2 to 12 weeks after device implantation, the rate of initial follow-up improved appreciably over time. This CIED follow-up visit was significantly more common in white patients than in patients of other races.
Collapse
Affiliation(s)
- Sana M Al-Khatib
- Duke Clinical Research Institute, Department of Medicine, Duke University School of Medicine, Durham, NC 27715, USA.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Roka A, Schoenfeld MH. The pathway to physician reimbursement for cardiac implantable electronic devices (CIEDs): a history and brief synopsis. J Interv Card Electrophysiol 2012; 36:137-44. [PMID: 23242735 DOI: 10.1007/s10840-012-9747-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2012] [Accepted: 09/14/2012] [Indexed: 11/25/2022]
Abstract
Cardiac implantable electronic devices (CIEDs), despite their proven effectiveness in large clinical trials for a wide range of patients with arrhythmia and heart failure, are frequent targets for criticism regarding cost-efficiency and alleged overuse. Newer indications, such as sinus node dysfunction for pacemakers and primary prevention for implantable cardioverter-defibrillators, increased eligible patient population significantly. This lead to heightened scrutiny from payors and legislative agencies, such as prior authorization and mandatory registry participation. Despite the significant administrative burden, the efficiency of these measures to decrease abuse is not clear. In addition, professional societies, regulatory agencies, and payors may not always agree whether use of a device is appropriate for a given patient. The review focuses on past and current issues related to utilization of CIEDs, which lead to increased regulatory oversight, and the effort of professional societies, payors, and governmental agencies to improve access to these life-saving therapeutical modalities while maintaining a just and cost-efficient healthcare system.
Collapse
Affiliation(s)
- Attila Roka
- Yale University School of Medicine, Yale-New Haven Hospital, St. Raphael Campus, New Haven, CT, USA
| | | |
Collapse
|
13
|
McMullan J, Valento M, Attari M, Venkat A. Care of the pacemaker/implantable cardioverter defibrillator patient in the ED. Am J Emerg Med 2007; 25:812-22. [PMID: 17870488 DOI: 10.1016/j.ajem.2007.02.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2006] [Revised: 01/20/2007] [Accepted: 02/03/2007] [Indexed: 02/04/2023] Open
Abstract
As the population ages and the prevalence of cardiovascular disease increases, patients with pacemakers and implantable cardioverter defibrillators (ICDs) more commonly present to the emergency department. These patients can have complex medical issues related to and independent of their pacemaker/ICD that require careful management by the emergency physician. This article will review the major diagnostic and therapeutic considerations in the emergency care of patients with pacemakers and ICDs.
Collapse
Affiliation(s)
- Jason McMullan
- Department of Emergency Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0769, USA
| | | | | | | |
Collapse
|
14
|
Nazarian S, Roguin A, Zviman MM, Lardo AC, Dickfeld TL, Calkins H, Weiss RG, Berger RD, Bluemke DA, Halperin HR. Clinical utility and safety of a protocol for noncardiac and cardiac magnetic resonance imaging of patients with permanent pacemakers and implantable-cardioverter defibrillators at 1.5 tesla. Circulation 2006; 114:1277-84. [PMID: 16966586 PMCID: PMC3410556 DOI: 10.1161/circulationaha.105.607655] [Citation(s) in RCA: 239] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Magnetic resonance imaging (MRI) is an important diagnostic modality currently unavailable for millions of patients because of the presence of implantable cardiac devices. We sought to evaluate the diagnostic utility and safety of noncardiac and cardiac MRI at 1.5T using a protocol that incorporates device selection and programming and limits the estimated specific absorption rate of MRI sequences. METHODS AND RESULTS Patients with no imaging alternative and with devices shown to be MRI safe by in vitro phantom and in vivo animal testing were enrolled. Of 55 patients who underwent 68 MRI studies, 31 had a pacemaker, and 24 had an implantable defibrillator. Pacing mode was changed to "asynchronous" for pacemaker-dependent patients and to "demand" for others. Magnet response and tachyarrhythmia functions were disabled. Blood pressure, ECG, oximetry, and symptoms were monitored. Efforts were made to limit the system-estimated whole-body average specific absorption rate to 2.0 W/kg (successful in >99% of sequences) while maintaining the diagnostic capability of MRI. No episodes of inappropriate inhibition or activation of pacing were observed. There were no significant differences between baseline and immediate or long-term (median 99 days after MRI) sensing amplitudes, lead impedances, or pacing thresholds. Diagnostic questions were answered in 100% of nonthoracic and 93% of thoracic studies. Clinical findings included diagnosis of vascular abnormalities (9 patients), diagnosis or staging of malignancy (9 patients), and assessment of cardiac viability (13 patients). CONCLUSIONS Given appropriate precautions, noncardiac and cardiac MRI can potentially be safely performed in patients with selected implantable pacemaker and defibrillator systems.
Collapse
Affiliation(s)
- Saman Nazarian
- Department of Cardiology, Johns Hopkins Hospital, Carnegie 568, 600 N Wolfe St, Baltimore, MD 21287, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|